戈尔卡多米德:一种口服CELMoD剂,针对IKZF1/3的扩散大B细胞淋巴瘤
Zhongying Mo1, Lynda Groocock1, Scott Wood1
1Protein Homeostasis (PH) Thematic Research Center (TRC), Bristol Myers Squibb, San Diego, California.
Blood cancer discovery
|November 3, 2025
概括
戈尔卡多米德是一种新的口服大脑细胞调节剂,在扩散型大B细胞淋巴瘤 (DLBCL) 临床前模型中显示了关键蛋白质的强烈降解. 这种候选药物在治疗DLBCL,特别是耐火病例方面显示出显著的前景.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 扩散型大B细胞淋巴瘤 (DLBCL) 是一种具有攻击性的血液性恶性瘤,对耐药患者的治疗选择有限.
- 目前用于DLBCL的治疗方法经常面临有效性和患者预后的挑战.
研究的目的:
- 报告golcadomide (CC-99282) 的发现和临床前评估,这是一种用于DLBCL治疗的新型大脑调节CELMoD剂.
- 评估戈尔卡多米德的作用机制,抗瘤活性,以及作为候选药物的潜力.
主要方法:
- 在临床前模型中评估了golcadomide对IKZF1和IKZF3的降解.
- 在人类淋巴瘤细胞系和老鼠异种移植中评估了抗瘤活性.
- 药理学和CRISPR查确定了潜在的基因和途径.
主要成果:
- 戈尔卡多米德显示了IKZF1和IKZF3的快速,深度和持续的降解,超过了莱纳利多米德的活性.
- 该药物降低了MYC的调节,促进了细胞亡,并在淋巴瘤细胞中诱导免疫细胞死亡.
- 戈尔卡多米德偏好地分布在淋巴瘤组织中,导致瘤回归和无瘤结果在体内得到改善.
结论:
- 戈尔卡多米德通过向蛋白质降解,对DLBCL表现出强大而广泛的抗瘤活性.
- 这些临床前发现强烈支持黄卡多米德作为DLBCL有前途的治疗候选药物,需要进一步的临床研究.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
9.4K
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
830
相关概念视频
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
01:31Immunoglobulin-like Cell Adhesion Molecules
4.1K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
4.1K